REDWOOD CITY, Calif., June 3, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced a presentation of clinical trial results on its hypoxia-activated prodrug, TH-302. The presentation will take place at the ASCO Annual Meeting being held June 4 to 8, 2010, at the McCormick Place Convention Center in Chicago, Illinois.
The following poster presentation will take place:
Phase I/II study of TH-302 Combined with Doxorubicin in Soft Tissue Sarcoma
Cranmer et al., Sunday, June 6 from 2:00 p.m. – 6:00 p.m. Central Time (abstract 10036).
Copies of the poster may be obtained after the poster session by contacting the Company.
The Company will also host an Investor Meeting at ASCO. Clinical trial investigators will present updated clinical trial results from all ongoing clinical trials of TH-302. The Investor Meeting will take place on Sunday, June 6, 2010 at ZED451, The Fireside Room, 739 N. Clark Street, Chicago, Illinois, from 6:30 to 7:30 p.m. Central Time. An audio webcast with slides of the Investor Meeting will be available over the internet following the meeting and can be accessed from Threshold's website, www.thresholdpharm.com, under Investors & Media.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website (www.thresholdpharm.com).
Forward-Looking Statements
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold's product candidates, and potential therapeutic uses and benefits of our product candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to commence its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on May 6, 2010 and is available from the SEC's website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading "Investors." We do not intend to update any forward-looking statement made in this news release.